The ABPI has appointed Dr Jacintha Sivarajah as the Association’s new Head of Medical Affairs - reporting directly to ABPI’s Executive Research Medical and Innovation Director Dr Virginia Acha.
Jacintha will be responsible for leading our policy work on medical practice and clinical research and for representing our industry with our key stakeholders in the healthcare services, professional societies and medical and clinical research organisations.
In her most recent role Dr Sivarajah worked for GSK as Medical Affairs Manager of the haematology-Oncology team and prior to this worked as a Senior Medical Advisor supporting their haematology-oncology portfolio. Prior to joining GSK Dr Sivarajah worked for Sanofi for three years supporting their Cardiovascular, Thrombosis and Diabetes portfolios.
Dr Jacintha Sivarajah qualified as a physician from King’s College London in 2002 and worked for a number of years within the NHS whilst also undertaking a training programme in internal medicine obtaining her MRCP (Member of the Royal College of Physicians) qualification in 2006.
Welcoming Dr Sivarajah’s appointment ABPI Executive Research Medical and Innovation Director Dr Virginia Acha said: “Jacintha joins our team at ABPI at a time when medicines innovation, clinical benefit and our ways of working with researchers and healthcare practitioners are in the spotlight. Her range of experience will be hugely beneficial to members and colleagues in clinical research and development. Jacintha has the right skill set to deliver the end to end medical affairs support we need at ABPI, and I know she is going to be a much valued member of our team”.
Commenting on her appointment Dr Sivarajah said: “I am really excited to be joining at the ABPI at a time when research and development is high on the agenda in the UK. As a physician, it gives me no greater pleasure than to see the availability of new, effective treatments that aim to improve the health and well-being of patients. I am looking forward to being part of the team that helps to represent the industry and its aspiration within the UK to discover, develop and deliver innovative medicines to patients.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com